What Cephalosporin Antibiotics Are Recommended for Treating Enteritis?

When treating bacterial gastroenteritis—commonly referred to as “infectious diarrhea”—clinicians do not routinely prescribe cephalosporin antibiotics, including first- through fourth-generation agents such as cefazolin, cefuroxime, ceftriaxone, or cefepime. Most cases of acute gastroenteritis are caused by viruses (e.g., norovirus, rotavirus) or self-limiting bacterial pathogens (e.g., *Campylobacter jejuni*, *Salmonella* spp., *Shigella* spp.), for which supportive care—including oral rehydration therapy and electrolyte replacement—is the cornerstone of management.

Cephalosporins are reserved for specific, clinically indicated scenarios: severe systemic infection, immunocompromised status, documented invasive bacterial infection (e.g., bacteremia, extraintestinal spread), or confirmed pathogens with known resistance patterns that necessitate broader-spectrum coverage. Even then, choice of agent depends on local antimicrobial susceptibility data, pharmacokinetic properties, and risk of collateral damage—including disruption of gut microbiota and selection for multidrug-resistant organisms.

Empiric use of cephalosporins for uncomplicated gastroenteritis is discouraged by major guidelines—including those from the Infectious Diseases Society of America (IDSA) and the World Health Organization (WHO)—due to lack of clinical benefit, potential for adverse effects (e.g., hypersensitivity reactions, *Clostridioides difficile* infection), and contribution to global antimicrobial resistance.

Patients experiencing persistent fever, bloody diarrhea, severe abdominal pain, signs of sepsis, or symptoms lasting beyond 7–10 days should undergo diagnostic evaluation—including stool culture, multiplex PCR testing, and blood work—to determine whether targeted antimicrobial therapy is warranted. Any antibiotic decision must be individualized and guided by microbiological evidence and clinical context—not symptom-based assumptions.